Insider Buying: Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) COO Buys 555,556 Shares of Stock

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) COO Denise P. Carter bought 555,556 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $0.45 per share, with a total value of $250,000.20. Following the completion of the purchase, the chief operating officer now owns 602,648 shares of the company’s stock, valued at $271,191.60. This trade represents a 1,179.72 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Quoin Pharmaceuticals Trading Down 1.6 %

Shares of NASDAQ QNRX opened at $0.55 on Friday. The company has a market cap of $2.78 million, a price-to-earnings ratio of -0.14 and a beta of 1.79. The stock’s 50 day simple moving average is $0.68 and its 200 day simple moving average is $0.63. Quoin Pharmaceuticals, Ltd. has a 12-month low of $0.43 and a 12-month high of $6.18.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.